Watkins Tim 4

What Happened
Tim Watkins, Contineum Therapeutics' Chief Medical Officer & Head of Development, exercised 3,611 option shares (exercise price $4.50) on March 2, 2026 for a cash outlay of $16,250 and immediately sold those 3,611 shares in the open market for total proceeds of approximately $54,220 (weighted average sale price $15.02). The filing shows the options converted to shares and those shares were disposed the same day.

Key Details

• Transaction date: 2026-03-02 (filed same day).
• Exercise: 3,611 option shares at $4.50 each = $16,250 total (derivative exercise, code M).
• Sale: 3,611 shares sold in open market at a weighted average of $15.02 = $54,220 total (code S). Sales executed in multiple trades at prices ranging $14.60–$15.41.
• Net proceeds before fees/taxes: ~ $37,970 (sale proceeds minus exercise cost).
• Plan: Transactions were executed under a 10b5‑1 trading plan adopted Sept 23, 2025 (footnote F1).
• Vesting note: One-half of the option grant vested Oct 28, 2025; the remainder vests in 36 equal monthly installments subject to continued service (footnote F3).
• Shares owned after the transaction: not disclosed in the information provided on this Form 4.
• Filing timeliness: Reported on the same day as the transactions (no late filing indicated).

Context
This was an option exercise followed by an immediate open‑market sale (commonly a cashless outcome), executed under a pre-established 10b5‑1 plan — a routine way executives monetize vested option shares without ongoing insider trading decisions. Footnote F2 notes the sale price shown is a weighted average and the filer can provide a breakdown of individual trade prices on request.